Jedidiah I Morton (Jedidiah Morton)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 37

Top Topics

Systematic Review

Acute Kidney Injury

Cardiac Resynchronization Therapy

Top Venues

PharmacoEconomics

Journal of diabetes

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Clara Marquina, Jedidiah I Morton, Melanie A Lloyd, Dina Abushanab, Yeji Baek, Tamrat Befekadu Abebe, Adam C Livori MClinPharm, Padam Kanta Dahal, Gerald F Watts, Zanfina Ademi
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review. PharmacoEconomics 42 (4) (2024)
Clara Marquina, Jedidiah I Morton, Melanie A Lloyd, Dina Abushanab, Yeji Baek, Tamrat Befekadu Abebe, Adam C Livori MClinPharm, Padam Kanta Dahal, Gerald F Watts, Zanfina Ademi
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review. PharmacoEconomics 42 (4) (2024)
Kate E D Ziser, Adam C Livori MClinPharm, Jedidiah I Morton, Adaire E Prosser, Jenni S Ilomaki, Stephen J Wood
Acute kidney injury, renal impairment and renal failure associated with sodium glucose co-transporter-2 inhibitors in at-risk groups: A systematic review. British journal of clinical pharmacology 90 (7) (2024)
Kate E D Ziser, Stephen J Wood, George S Q Tan, Jedidiah I Morton, Jonathan Edward Shaw, J Simon Bell, Jenni S Ilomaki
The association between sodium glucose cotransporter-2 inhibitors vs dipeptidyl peptidase-4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population-based cohort study. Journal of diabetes 16 (4) (2024)
Kate E D Ziser, Stephen J Wood, George S Q Tan, Jedidiah I Morton, Jonathan Edward Shaw, J Simon Bell, Jenni S Ilomaki
The association between sodium glucose cotransporter-2 inhibitors vs dipeptidyl peptidase-4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population-based cohort study. Journal of diabetes 16 (4) (2024)
Clara Marquina, Jedidiah I Morton, Melanie A Lloyd, Dina Abushanab, Yeji Baek, Tamrat Befekadu Abebe, Adam C Livori MClinPharm, Padam Kanta Dahal, Gerald F Watts, Zanfina Ademi
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review. PharmacoEconomics (2024)
George S Q Tan, Jedidiah I Morton, Stephen J Wood, Jonathan Edward Shaw, Dianna J Magliano, Jenni S Ilomaki
SGLT-2 Inhibitor Use and Cause-Specific Hospitalization Rates: An Outcome-Wide Study to Identify Novel Associations of SGLT-2 Inhibitors. Clinical pharmacology and therapeutics (2024)
Clara Marquina, Jedidiah I Morton, Melanie A Lloyd, Dina Abushanab, Yeji Baek, Tamrat Befekadu Abebe, Adam C Livori MClinPharm, Padam Kanta Dahal, Gerald F Watts, Zanfina Ademi
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review. PharmacoEconomics 42 (4) (2024)
Kate E D Ziser, Adam C Livori MClinPharm, Jedidiah I Morton, Adaire E Prosser, Jenni S Ilomaki, Stephen J Wood
Acute kidney injury, renal impairment and renal failure associated with sodium glucose co-transporter-2 inhibitors in at-risk groups: A systematic review. British journal of clinical pharmacology 90 (7) (2024)
Kate E D Ziser, Adam C Livori MClinPharm, Jedidiah I Morton, Adaire E Prosser, Jenni S Ilomaki, Stephen J Wood
Acute kidney injury, renal impairment and renal failure associated with sodium glucose co-transporter-2 inhibitors in at-risk groups: A systematic review. British journal of clinical pharmacology (2024)
Kate E D Ziser, Stephen J Wood, George S Q Tan, Jedidiah I Morton, Jonathan Edward Shaw, J Simon Bell, Jenni S Ilomaki
The association between sodium glucose cotransporter-2 inhibitors vs dipeptidyl peptidase-4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population-based cohort study. Journal of diabetes 16 (4) (2024)
George S Q Tan, Jedidiah I Morton, Stephen J Wood, Jonathan Edward Shaw, Dianna J Magliano, Jenni S Ilomaki
SGLT-2 Inhibitor Use and Cause-Specific Hospitalization Rates: An Outcome-Wide Study to Identify Novel Associations of SGLT-2 Inhibitors. Clinical pharmacology and therapeutics 115 (6) (2024)
George S Q Tan, Jedidiah I Morton, Stephen J Wood, Jonathan Edward Shaw, Dianna J Magliano, Jenni S Ilomaki
SGLT-2 Inhibitor Use and Cause-Specific Hospitalization Rates: An Outcome-Wide Study to Identify Novel Associations of SGLT-2 Inhibitors. Clinical pharmacology and therapeutics 115 (6) (2024)
Clara Marquina, Jedidiah I Morton, Melanie A Lloyd, Dina Abushanab, Yeji Baek, Tamrat Befekadu Abebe, Adam C Livori MClinPharm, Padam Kanta Dahal, Gerald F Watts, Zanfina Ademi
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review. PharmacoEconomics 42 (4) (2024)
Clara Marquina, Jedidiah I Morton, Melanie A Lloyd, Dina Abushanab, Yeji Baek, Tamrat Befekadu Abebe, Adam C Livori MClinPharm, Padam Kanta Dahal, Gerald F Watts, Zanfina Ademi
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review. PharmacoEconomics 42 (4) (2024)
Clara Marquina, Jedidiah I Morton, Melanie A Lloyd, Dina Abushanab, Yeji Baek, Tamrat Befekadu Abebe, Adam C Livori MClinPharm, Padam Kanta Dahal, Gerald F Watts, Zanfina Ademi
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review. PharmacoEconomics 42 (4) (2024)
Dina Abushanab, Daoud Al-Badriyeh, Clara Marquina, Jedidiah I Morton, Melanie A Lloyd, Ella Zomer, Stella Samoborec, Danny Liew, Zanfina Ademi
The Reduction of the Productivity Burden of Cardiovascular Disease by Improving the Risk Factor Control Among Australians with Type 2 Diabetes: A 10-Year Dynamic Analysis. European journal of preventive cardiology (2024)
Clara Marquina, Jedidiah I Morton, Melanie A Lloyd, Dina Abushanab, Yeji Baek, Tamrat Befekadu Abebe, Adam C Livori MClinPharm, Padam Kanta Dahal, Gerald F Watts, Zanfina Ademi
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review. PharmacoEconomics 42 (4) (2024)
Clara Marquina, Jedidiah I Morton, Melanie A Lloyd, Dina Abushanab, Yeji Baek, Tamrat Befekadu Abebe, Adam C Livori MClinPharm, Padam Kanta Dahal, Gerald F Watts, Zanfina Ademi
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review. PharmacoEconomics 42 (4) (2024)
Kate E D Ziser, Stephen J Wood, George S Q Tan, Jedidiah I Morton, Jonathan Edward Shaw, J Simon Bell, Jenni S Ilomaki
The association between sodium glucose cotransporter-2 inhibitors vs dipeptidyl peptidase-4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population-based cohort study. Journal of diabetes 16 (4) (2024)
Tamrat Befekadu Abebe, Jedidiah I Morton, Jenni S Ilomaki, Zanfina Ademi
Future burden of myocardial infarction in Australia: impact on health outcomes between 2019 and 2038. European heart journal. Quality of care & clinical outcomes (2023)
Adam C Livori MClinPharm, Zanfina Ademi, Jenni Ilomäki, Derk Pol, Jedidiah I Morton, J Simon Bell
Use of secondary prevention medications in metropolitan and non-metropolitan areas: an analysis of 41,925 myocardial infarctions in Australia. European journal of preventive cardiology (2023)
Clara Marquina, Jedidiah I Morton, Tom Brett, Melanie A Lloyd, Janette Radford, Clare F Heal, Charlotte Mary Hespe, Gerard Gill, David R Sullivan, Ella Zomer, Ian W Li, Jing Pang, Gerald F Watts, Zanfina Ademi
Enhancing the Detection and Care of Heterozygous Familial Hypercholesterolemia in Primary Care: Cost-Effectiveness and Return on Investment. Circulation. Genomic and precision medicine (2023)
Dina Abushanab, Clara Marquina, Jedidiah I Morton, Daoud Al-Badriyeh, Melanie A Lloyd, Dianna J Magliano, Danny Liew, Zanfina Ademi
Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022-2031. PharmacoEconomics (2023)
Jedidiah I Morton, Jenni Ilomäki, Stephen J Wood, J Simon Bell, Quan Huynh, Dianna J Magliano, Jonathan E Shaw
Treatment gaps, 1-year readmission and mortality following myocardial infarction by diabetes status, sex and socioeconomic disadvantage. Journal of epidemiology and community health 76 (7) (2022)
Peter A Lazzarini, Susanna M Cramb, Jonathan Golledge, Jedidiah I Morton, Dianna J Magliano, Jaap J Van Netten
Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century. Diabetologia 66 (2) (2022)
Jedidiah I Morton, Jenni Ilomӓki, Dianna J Magliano, Jonathan E Shaw
Persistent disparities in diabetes medication receipt by socio-economic disadvantage in Australia. Diabetic medicine : a journal of the British Diabetic Association 39 (9) (2022)
Peter A Lazzarini, Susanna M Cramb, Jonathan Golledge, Jedidiah I Morton, Dianna J Magliano, Jaap J Van Netten
Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century. Diabetologia 66 (2) (2022)
Peter A Lazzarini, Susanna M Cramb, Jonathan Golledge, Jedidiah I Morton, Dianna J Magliano, Jaap J Van Netten
Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century. Diabetologia 66 (2) (2022)
Peter A Lazzarini, Susanna M Cramb, Jonathan Golledge, Jedidiah I Morton, Dianna J Magliano, Jaap J Van Netten
Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century. Diabetologia (2022)
Jedidiah I Morton, Peter A Lazzarini, Jonathan E Shaw, Dianna J Magliano
Trends in the Incidence of Hospitalization for Major Diabetes-Related Complications in People With Type 1 and Type 2 Diabetes in Australia, 2010-2019. Diabetes care 45 (4) (2022)
Jedidiah I Morton, Clara Marquina, Jonathan Edward Shaw, Danny Liew, Kevan R Polkinghorne, Zanfina Ademi, Dianna J Magliano
Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. Diabetologia (2022)
Peter A Lazzarini, Susanna M Cramb, Jonathan Golledge, Jedidiah I Morton, Dianna J Magliano, Jaap J Van Netten
Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century. Diabetologia 66 (2) (2022)
Jedidiah I Morton, Julian W Sacre, Stephen P McDonald, Dianna J Magliano, Jonathan E Shaw
Excess all-cause and cause-specific mortality for people with diabetes and end-stage kidney disease. Diabetic medicine : a journal of the British Diabetic Association 39 (6) (2021)
Jedidiah I Morton, Stephen P McDonald, Agus Salim, Danny Liew, Jonathan Edward Shaw, Dianna J Magliano
Projecting the Incidence of Type 2 Diabetes-Related End-Stage Kidney Disease Until 2040: A Comparison Between the Effects of Diabetes Prevention and the Effects of Diabetes Treatment. Diabetes care 44 (7) (2021)
Jedidiah I Morton, Jenni S Ilomaki, Dianna J Magliano, Jonathan Edward Shaw
The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study. Diabetologia 64 (2) (2020)
Jedidiah I Morton, Danny Liew, Stephen P McDonald, Jonathan Edward Shaw, Dianna J Magliano
The Association Between Age of Onset of Type 2 Diabetes and the Long-term Risk of End-Stage Kidney Disease: A National Registry Study. Diabetes care 43 (8) (2020)